Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Dendreon Jumps on Upgrade

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Shares of Dendreon (NASDAQOTH: DNDNQ  ) soared 13% in early trading today after Sanford C. Bernstein upgraded the stock from "market-perform" to "outperform." Even better, Berstein singled out the drug company as potentially one of the top stocks of 2013. 

What it means
Any good news is welcome for long-suffering Dendreon. The stock actually traded above $50 per share back in 2010 after its prostate cancer drug Provenge was approved by the Food and Drug Administration. However, sales for Provenge were much lower than projected. As a result, Dendreon shares dropped more than 90% from its peak. 

Longtime readers of The Motley Fool know that we don't automatically fall into lockstep with analysts' opinions. However, when those opinions are based on solid fundamentals about the company, it pays to listen. Is that the case with Bernstein's upgrade of Dendreon?

Berstein analyst Geoffrey Porges commented that the market for Provenge is improving, despite competition from Medivation's (NASDAQ: MDVN  ) Xtandi and Johnson & Johnson's (NYSE: JNJ  ) Zytiga. Interviews with urologists found that they are frequently prescribing a combination of Provenge and Xtandi, according to Porges.

These comments are only anecdotal, but Dendreon's preliminary results for fourth quarter did confirm increased sales for Provenge. However, current growth rates won't allow the company to reach profitability soon.

Foolish take
It's a long shot for Dendreon to get back to its high levels of 2010. However, it doesn't need to do that for investors to achieve big gains. The landscape for Provenge does appear to be improving, although at a slower pace than Dendreon shareholders would prefer.

The good news, though, is that the opportunities for Provenge are still significant, and the stock could be poised to move up as the company capitalizes on these opportunities. Bernstein's upgrade seems to be right on target in my view.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2434060, ~/Articles/ArticleHandler.aspx, 9/29/2016 9:42:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 26 minutes ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
JNJ $117.27 Down -2.12 -1.78%
Johnson and Johnso… CAPS Rating: *****
MDVN $0.00 Down +0.00 +0.00%
Medivation CAPS Rating: ****